In conclusion, our study tested and validated for the first time the concept of inhibiting GHR/GH signaling in HCC by using pegvisomant, a drug that is already FDA approved, at multiple levels including in vitro and in vivo preclinical experiments as well as a pilot human study that demonstrated activity in sorafenib-resistant settings. This evidence concerns the gene GHR and hepatocellular carcinoma.